HC Wainwright Reiterates Buy Rating for Evolus (NASDAQ:EOLS)

HC Wainwright reissued their buy rating on shares of Evolus (NASDAQ:EOLS) in a research report report published on Thursday, Benzinga reports. HC Wainwright currently has a $27.00 price objective on the stock. HC Wainwright also issued estimates for Evolus’ Q4 2024 earnings at $0.01 EPS, FY2026 earnings at $0.40 EPS, FY2027 earnings at $1.31 EPS and FY2028 earnings at $2.18 EPS.

A number of other analysts have also recently issued reports on the company. Cantor Fitzgerald reaffirmed an overweight rating on shares of Evolus in a research report on Monday, September 16th. Needham & Company LLC reaffirmed a buy rating and set a $22.00 price target on shares of Evolus in a report on Friday, September 13th. Finally, Barclays lifted their price objective on shares of Evolus from $16.00 to $20.00 and gave the stock an overweight rating in a research report on Friday, September 13th.

Evolus Stock Performance

NASDAQ EOLS opened at $16.34 on Thursday. The firm has a market capitalization of $1.02 billion, a P/E ratio of -15.56 and a beta of 1.31. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 6.26. The firm’s fifty day moving average price is $15.13 and its two-hundred day moving average price is $13.27. Evolus has a 1 year low of $7.44 and a 1 year high of $17.70.

Evolus (NASDAQ:EOLS) last issued its earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The firm had revenue of $66.91 million for the quarter, compared to the consensus estimate of $65.06 million. As a group, research analysts anticipate that Evolus will post -0.64 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the transaction, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Perceptive Advisors LLC boosted its stake in shares of Evolus by 166.8% in the fourth quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock valued at $41,735,000 after buying an additional 2,477,623 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of Evolus by 5,627.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock valued at $10,276,000 after acquiring an additional 930,566 shares during the period. Lord Abbett & CO. LLC bought a new stake in shares of Evolus during the 1st quarter valued at $11,628,000. Armistice Capital LLC acquired a new stake in shares of Evolus during the 2nd quarter worth $3,906,000. Finally, Zimmer Partners LP bought a new position in shares of Evolus in the first quarter worth $4,200,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.